- Page 2 and 3: 2011Nurse’sDrugHandbook
- Page 4 and 5: Jones & Bartlett Learning2011Nurse
- Page 6: ContentsAdvisors, Reviewers, and Cl
- Page 9 and 10: ReviewersPeter J. Ambrose, PharmDAs
- Page 11 and 12: Reviewers and Clinical Consultants
- Page 13 and 14: How to Use This BookJones & Bartlet
- Page 15 and 16: Controlled substanceschedulesThe Co
- Page 17 and 18: time, however, this section doesn
- Page 19 and 20: The Physicians’ Desk Reference, t
- Page 21 and 22: 2Overview of Parmacologymodifiers,
- Page 23 and 24: 4Overview of Pharmacologysolutions,
- Page 25 and 26: 6Overview of Parmacologyinclude giv
- Page 27 and 28: Principles of Drug AdministrationBe
- Page 29 and 30: 10Principles of Drug Administration
- Page 31 and 32: Drug Therapy and the Nursing Proces
- Page 33 and 34: 14Drug Therapy and the Nursing Proc
- Page 36 and 37: abataceptOrenciaAClass and Category
- Page 38 and 39: forming a clot that eventually bloc
- Page 40 and 41: ponents, severe hepatic (Child-Pugh
- Page 44 and 45: failure; and dark brown urine may i
- Page 46 and 47: evening meals.DOSAGE ADJUSTMENT For
- Page 48 and 49: • Instruct patient to avoid hazar
- Page 50 and 51: phenytoin: Possibly decreased prote
- Page 52 and 53: candidates for systemic therapy or
- Page 54 and 55: Therapeutic class: AntiarrhythmicPr
- Page 57 and 58: 38alefaceptMechanism of ActionAlbut
- Page 59 and 60: 40Adverse ReactionsCNS: Asthenia, d
- Page 61 and 62: 42alglucerasehave had a hypotensive
- Page 65 and 66: 46almotriptan malateIndications and
- Page 67 and 68: 48alpha 1 -proteinase inhibitor (hu
- Page 69 and 70: 50alprostadiltoin level, causing ph
- Page 71 and 72: 52alteplase• Carefully examine pe
- Page 73 and 74: 54aluminum; alvimopan• Advise pat
- Page 75 and 76: 56Adverse ReactionsCNS: Agitation,
- Page 77 and 78: 58ambenonium chlorideambenoniumchlo
- Page 79 and 80: 60amikacin sulfate• Assess patien
- Page 81 and 82: 62aminocaproic acidbleeding, heartb
- Page 83 and 84: 64aminophyllineing theophylline pro
- Page 85 and 86: 66amiodarone hydrochlorideInteracti
- Page 87 and 88: 68InteractionsDRUGSanticholinergics
- Page 89 and 90: 70amlodipine besylateof seizures, u
- Page 91 and 92: 72amobarbital sodiumsuch as bananas
- Page 93 and 94:
74amoxapineachieved, a single dose
- Page 95 and 96:
76amphetamine sulfatereduced effect
- Page 97 and 98:
78amphotericin Bcinations, headache
- Page 99 and 100:
80amphotericin Bby adding 1 ml (5 m
- Page 101 and 102:
82ampicillinAdults and children wei
- Page 103 and 104:
84anagrelide hydrochloridePATIENT T
- Page 105 and 106:
86anastrozolereceiving etanercept o
- Page 107 and 108:
88anistreplasephenicol, chlorpropam
- Page 109 and 110:
90antihemophilic factoroccurs becau
- Page 111 and 112:
92antihemophilic factor To prevent
- Page 113 and 114:
94apomorphine hydrochlorideintracra
- Page 115 and 116:
96aprepitantCAPSULESAdults. 125 mg
- Page 117 and 118:
98argatrobanamines because arformot
- Page 119 and 120:
100Adverse ReactionsCNS: Abnormal g
- Page 121 and 122:
102Adverse ReactionsCNS: Agitation,
- Page 123 and 124:
104Ancasal (CAN), Apo-As (CAN), Apo
- Page 125 and 126:
106atenololAspirin inhibits platele
- Page 127 and 128:
108atomoxetine hydrochloride• Whi
- Page 129 and 130:
110atorvastatin calciumHMG-CoA redu
- Page 131 and 132:
112Nursing Considerations• Use at
- Page 133 and 134:
114atropineMechanism of ActionInhib
- Page 135 and 136:
116azathioprinecreatinine levels, p
- Page 137 and 138:
118azithromycineral H 1 receptors,
- Page 139 and 140:
120aztreonamasthenia, dizziness, fa
- Page 141 and 142:
122aztreonamnormal saline solution,
- Page 143 and 144:
124bacitracinnia, neutropenia, prol
- Page 145 and 146:
126baclofen4 to 8 hr, if symptoms d
- Page 147 and 148:
128basiliximabdecreased or delayed
- Page 149 and 150:
130• If patient has acute asthma
- Page 151 and 152:
132Adverse ReactionsCNS: Anxiety, a
- Page 153 and 154:
134benzquinamide hydrochloride; ben
- Page 155 and 156:
136Adverse ReactionsCNS: Amnesia, a
- Page 157 and 158:
138betamethasoneAdults with foot te
- Page 159 and 160:
140Adverse ReactionsCNS: Amnesia, a
- Page 161 and 162:
142biperidenallowing contraction st
- Page 163 and 164:
144bisoprolol fumarateContraindicat
- Page 165 and 166:
146bivalirudin• Expect therapy to
- Page 167 and 168:
148bosentanMechanism of ActionBosen
- Page 169 and 170:
150bromocriptine mesylateMechanism
- Page 171 and 172:
152budesonidemonary fibrosisOther:
- Page 173 and 174:
154budesonideEENT: Bad taste, catar
- Page 175 and 176:
156buprenorphine hydrochloridedizzi
- Page 177 and 178:
158buspirone hydrochlorideAdverse R
- Page 179 and 180:
160butabarbital sodiumELIXIR, TABLE
- Page 181 and 182:
162butrophanol tartrateContraindica
- Page 183 and 184:
164cabergolineclosely for evidence
- Page 185 and 186:
166calcitonincinosis, and other sof
- Page 187 and 188:
168calciumCAPSULES, ORAL SOLUTIONAd
- Page 189 and 190:
170calciumbeta blockadecalcitonin:
- Page 191 and 192:
172capreomycin sulfatenificant or p
- Page 193 and 194:
174carbamazepineInteractionsDRUGSal
- Page 195 and 196:
176carbamazepineziprasidone, zonisa
- Page 197 and 198:
178Nursing ConsiderationsWARNING Be
- Page 199 and 200:
180caspofungin acetatecatecholamine
- Page 201 and 202:
182cefaclorreach room temperature.
- Page 203 and 204:
184cefadroxil2 g daily or in divide
- Page 205 and 206:
186Indications and Dosages To treat
- Page 207 and 208:
188Mechanism of ActionInterferes wi
- Page 209 and 210:
190cefepime hydrochloridesporin, 7-
- Page 211 and 212:
192cefmetazole sodiumHEME: Eosinoph
- Page 213 and 214:
194Nursing Considerations• Use ce
- Page 215 and 216:
196cefotaxime sodiumNursing Conside
- Page 217 and 218:
198cefotetan disodium• Protect ce
- Page 219 and 220:
200cefoxitin sodiumChildren age 3 m
- Page 221 and 222:
202cefprozilby inhibiting the final
- Page 223 and 224:
204ceftazidimeIndications and Dosag
- Page 225 and 226:
206ceftizoxime sodiumto 2.25 mg/kg
- Page 227 and 228:
208ContraindicationsCalcium-contain
- Page 229 and 230:
210cefuroxime• Assess for perinea
- Page 231 and 232:
212celecoxibtor or at room temperat
- Page 233 and 234:
214cephalexinthrombotic events, inc
- Page 235 and 236:
216cephapirin sodiumwith fluids, el
- Page 237 and 238:
218certolizumab pegolCV: EdemaEENT:
- Page 239 and 240:
220cevimeline hydrochlorideshaking.
- Page 241 and 242:
222chloramphenicolContraindications
- Page 243 and 244:
224chlordiazepoxide hydrochlorideIn
- Page 245 and 246:
226chlorphenesin carbamatecalcium:
- Page 247 and 248:
228chlorpromazineor weighing 50 to
- Page 249 and 250:
230chlorpropamide• For I.V. injec
- Page 251 and 252:
232chlorthalidoneor severe hypoglyc
- Page 253 and 254:
234cholestyramineHEME: Agranulocyto
- Page 255 and 256:
236ciclesonideacts on the heat-regu
- Page 257 and 258:
238Nursing Considerations• Monito
- Page 259 and 260:
240cinacalcet hydrochlorideCimetidi
- Page 261 and 262:
242ciprofloxacinspecies, Proteus mi
- Page 263 and 264:
244Nursing Considerations• Obtain
- Page 265 and 266:
246citalopram hydrobromideIndicatio
- Page 267 and 268:
248Nursing Considerations• Expect
- Page 269 and 270:
250clindamycinPATIENT TEACHING• I
- Page 271 and 272:
252clofibrateto be used into the ca
- Page 273 and 274:
254clonazepamNursing Considerations
- Page 275 and 276:
256clonidineand management of epidu
- Page 277 and 278:
258clorazepate dipotassiumSKIN: Ery
- Page 279 and 280:
260clozapineIncompatibilitiesDon’
- Page 281 and 282:
262coagulation factor VIIa (recombi
- Page 283 and 284:
264colchicinepresses cough by actin
- Page 285 and 286:
266colchicinehalved and not repeate
- Page 287 and 288:
268colestipol hydrochloride• Make
- Page 289 and 290:
270conivaptan hydrochlorideIf patie
- Page 291 and 292:
272cortisone acetateFor adrenocorti
- Page 293 and 294:
274cromolyn sodiumMechanism of Acti
- Page 295 and 296:
276cyclobenzaprine hydrochloridebef
- Page 297 and 298:
278cyclosporineOther: Folic acid de
- Page 299 and 300:
280cyclosporineWARNING Watch for ev
- Page 301 and 302:
282dalteparin sodiumContraindicatio
- Page 303 and 304:
284dantrolene sodiumIndications and
- Page 305 and 306:
286Adverse ReactionsCNS: Anxiety, a
- Page 307 and 308:
288darbepoetin alfaover 4 wk but on
- Page 309 and 310:
290decitabinewhich relieves sensati
- Page 311 and 312:
292obtain baseline assessment of pa
- Page 313 and 314:
294desipramine hydrochloridepseudom
- Page 315 and 316:
296desmopressin acetateNasal Soluti
- Page 317 and 318:
298Mechanism of ActionBinds to intr
- Page 319 and 320:
300dexamethasonehypokalemic alkalos
- Page 321 and 322:
302dexmethylphenidate hydrochloride
- Page 323 and 324:
304Indications and Dosages To treat
- Page 325 and 326:
306diazepamInteractionsDRUGSCNS dep
- Page 327 and 328:
308diazepamatric effects, sedation,
- Page 329 and 330:
310Nursing Considerations• Becaus
- Page 331 and 332:
312diclofenacreport evidence of blo
- Page 333 and 334:
314dicloxacillin sodium• Advise p
- Page 335 and 336:
316dicyclomine hydrochloridecycloph
- Page 337 and 338:
318diflunisaldiflunisalApo-Diflunis
- Page 339 and 340:
320digoxindoses given every 6 to 8
- Page 341 and 342:
322Nursing Considerations• Expect
- Page 343 and 344:
324dihydrotachysteroltaxis, nasal c
- Page 345 and 346:
326diltiazem hydrochlorideMechanism
- Page 347 and 348:
328dimenhydrinateChildren. 1.25 mg/
- Page 349 and 350:
330dipyridamoleContraindicationsBla
- Page 351 and 352:
332InteractionsDRUGSantiarrhythmics
- Page 353 and 354:
334disulfiramIndications and Dosage
- Page 355 and 356:
336docusatecyclopropane, halothane:
- Page 357 and 358:
338dofetilideDOSAGE ADJUSTMENT Init
- Page 359 and 360:
340donepezil hydrochloridecardia, w
- Page 361 and 362:
342dopamine hydrochlorideperipheral
- Page 363 and 364:
344doxapram hydrochlorideremove 55
- Page 365 and 366:
346doxepin hydrochlorideWARNING Mon
- Page 367 and 368:
348doxercalciferolevery other day)
- Page 369 and 370:
350doxycycline50 to 100 mg (base) e
- Page 371 and 372:
352dronabinolon an empty stomach.
- Page 373 and 374:
354Indications and Dosages To reduc
- Page 375 and 376:
356drotrecogin alfacholinergic, suc
- Page 377 and 378:
358duloxetine hydrochlorideincrease
- Page 379 and 380:
360dyphyllineTestosteroneTestostero
- Page 382 and 383:
E FecallantideKalbitorClass and Cat
- Page 384 and 385:
Maximum: 40 mg as single dose, 80 m
- Page 386 and 387:
eltrombopag within any 24-hour peri
- Page 388 and 389:
• Monitor patient closely for ang
- Page 390 and 391:
enoxaparin sodiumLovenoxClass and C
- Page 392 and 393:
to rub the site after giving the in
- Page 394 and 395:
negative feedback• postsynaptic a
- Page 396 and 397:
Therapeutic class: Antihypertensive
- Page 398 and 399:
Nursing Considerations• Use epoet
- Page 400 and 401:
• During prolonged infusion, watc
- Page 402 and 403:
closely throughout therapy.• Advi
- Page 404 and 405:
coccus species, Bacteroides fragili
- Page 406 and 407:
erythromycinlactobionate(contains 5
- Page 408 and 409:
ergotamine usehepatotoxic drugs: In
- Page 410 and 411:
tonergic effects of escitalopramMAO
- Page 412 and 413:
hypotensionGI: Nausea, vomitingRESP
- Page 414 and 415:
mixed with normal saline solution o
- Page 416 and 417:
women. Initial: 0.025 to 0.05 mg da
- Page 418 and 419:
mones are required for normal genit
- Page 420 and 421:
• Expect to stop estrogen therapy
- Page 422 and 423:
on days 1 through 14 and combinatio
- Page 424 and 425:
may increase risk of dementia, hear
- Page 426 and 427:
etanercept 407Mechanism of ActionEt
- Page 428 and 429:
amphotericin B: Increased risk of e
- Page 430 and 431:
ethchlorvynolPlacidylClass, Categor
- Page 432 and 433:
loxapine, MAO inhibitors, maprotili
- Page 434 and 435:
• Monitor patient for signs and s
- Page 436 and 437:
E.R. TABLETSAdults. 400 to 1,000 mg
- Page 438 and 439:
cose levels in patients with type 2
- Page 440 and 441:
famotidine 421Mechanism of ActionRe
- Page 442 and 443:
famotidine 423Mechanism of ActionIn
- Page 444 and 445:
that NSAIDs or colchicine may be pr
- Page 446 and 447:
decreased therapeutic effect of fel
- Page 448 and 449:
• Advise patient to have laborato
- Page 450 and 451:
sophageal reflux disease; GI bleedi
- Page 452 and 453:
transmitter release from afferent n
- Page 454 and 455:
touch or overlap. Instruct patient
- Page 456 and 457:
TABLETS, E.R. CAPSULES, E.R. TABLET
- Page 458 and 459:
abdominal painGU: Dysuria, urine re
- Page 460 and 461:
metabolite (5-alpha dihydrotestoste
- Page 462 and 463:
CV: Arrhythmias, chest pain, heart
- Page 464 and 465:
fludrocortisoneacetateFlorinefClass
- Page 466 and 467:
agitation, dysphoria, and increased
- Page 468 and 469:
ment or concurrent illness, those w
- Page 470 and 471:
Adolescents and children age 12. In
- Page 472 and 473:
depressionlevodopa: Possibly decrea
- Page 474 and 475:
and antipyretic actions of flurbipr
- Page 476 and 477:
into the air (away from her eyes an
- Page 478 and 479:
antihistamines: Increased risk of i
- Page 480 and 481:
idone: Possibly increased folic aci
- Page 482 and 483:
• Store drug at a controlled room
- Page 484 and 485:
Indications and Dosages To treat un
- Page 486 and 487:
sive therapy may resume, as prescri
- Page 488 and 489:
hemiplegia, hostility, hypoesthesia
- Page 490 and 491:
with peripheral vascular disease be
- Page 492 and 493:
ORAL SOLUTION, TABLETSAdults. 20 to
- Page 494 and 495:
G H IgabapentinNeurontinClass and C
- Page 496 and 497:
than 9 ml/min/1.73 m 2 )Interaction
- Page 498 and 499:
for bacterial growth, thereby causi
- Page 500 and 501:
ate sites.ContraindicationsHypersen
- Page 502 and 503:
insufficiency. Also be aware that h
- Page 504 and 505:
glucagonGlucaGen, Glucagon Diagnost
- Page 506 and 507:
danazol, diazoxide, estrogen, gluca
- Page 508 and 509:
hage with unstable cardiovascular s
- Page 510 and 511:
where tuberculosis and histoplasmos
- Page 512 and 513:
Indications and Dosages To relieve
- Page 514 and 515:
sympathetic nerve endings. Through
- Page 516 and 517:
Nursing Considerations• Use guanf
- Page 518 and 519:
ContraindicationsBlood dyscrasias,
- Page 520 and 521:
To diagnose and treat disseminatedi
- Page 522 and 523:
hyaluronan (high-molecular-weight);
- Page 524 and 525:
symptoms, such as arthralgia, fever
- Page 526 and 527:
hydrocortisone(cortisol)Cortef, Cor
- Page 528 and 529:
hydromorphone hydrochloride 509Nurs
- Page 530 and 531:
immediate-release nonopioid analges
- Page 532 and 533:
increases renal excretion of drug.P
- Page 534 and 535:
cholinergic effectsantidiarrheals (
- Page 536 and 537:
hypoprothrombinemia and GI bleeding
- Page 538 and 539:
nonsustained ventricular tachycardi
- Page 540 and 541:
explain that adjustment process wil
- Page 542 and 543:
CNS depressants: Increased CNS depr
- Page 544 and 545:
immune globulin 525increase in plat
- Page 546 and 547:
antibody complexes produce split co
- Page 548 and 549:
Therapeutic class: Antihypertensive
- Page 550 and 551:
InteractionsDRUGSNote: All effects
- Page 552 and 553:
stays in rectum at least 1 hour.•
- Page 554 and 555:
piratory tract infections and UTI a
- Page 556 and 557:
irbesartan 537Mechanism of ActionAf
- Page 558 and 559:
iron dextran(contains 50 mg of elem
- Page 560 and 561:
trophil function. Iron sucrose inje
- Page 562 and 563:
educed-alcohol and alcohol-free bee
- Page 564 and 565:
EENT: Choking sensation, eyelid or
- Page 566 and 567:
isoproterenol(isoprenaline)Isupreli
- Page 568 and 569:
isosorbide dinitrateApo-ISDN (CAN),
- Page 570 and 571:
isotretinoinAccutane, ClaravisClass
- Page 572 and 573:
Mechanism of ActionInhibits calcium
- Page 574 and 575:
Possibly inhibited metabolism of th
- Page 576 and 577:
kanamycin sulfate 557J K Lkanamycin
- Page 578 and 579:
Adverse ReactionsCNS: Headache, irr
- Page 580 and 581:
hemorrhagic diathesis; history of G
- Page 582 and 583:
labetalolhydrochlorideNormodyne, Tr
- Page 584 and 585:
• Watch patient closely for suici
- Page 586 and 587:
Adults and adolescents age 16 and o
- Page 588 and 589:
Additive depressive effects on hear
- Page 590 and 591:
ding, cottage cheese, yogurt, or st
- Page 592 and 593:
Indications and Dosages To relieve
- Page 594 and 595:
starting. If APTT is below target r
- Page 596 and 597:
patients treated for precocious cen
- Page 598 and 599:
of epileptiform burst firing. Levet
- Page 600 and 601:
levodopa 581Mechanism of ActionBy s
- Page 602 and 603:
levofloxacin 583TABLETS, I.V. INFUS
- Page 604 and 605:
diarrhea, even if it’s more than
- Page 606 and 607:
P.O. administration is tolerated.Ch
- Page 608 and 609:
in a 24-hr period. To provide topic
- Page 610 and 611:
WARNING Monitor patient for hyperse
- Page 612 and 613:
linezolid 593Mechanism of ActionLin
- Page 614 and 615:
• Reassure patient with tooth dis
- Page 616 and 617:
liraglutide also delays gastric emp
- Page 618 and 619:
stimulant dosages increase risk of
- Page 620 and 621:
anes, or tongue, notify prescriber
- Page 622 and 623:
or other flavored drink before givi
- Page 624 and 625:
mation or pain; advise her to rest
- Page 626 and 627:
digoxin: Possibly increased blood d
- Page 628 and 629:
Therapeutic class: Antihyperlipidem
- Page 630 and 631:
dopamine: Possibly decreased alphaa
- Page 632 and 633:
magnesium 613Mmagnesium chloride(co
- Page 634 and 635:
cholecystokinin. This substance sti
- Page 636 and 637:
urine output of 100 to 500 ml/hr wi
- Page 638 and 639:
• Watch patient (especially child
- Page 640 and 641:
teritis; gastroesophageal reflux di
- Page 642 and 643:
common but serious adverse GI react
- Page 644 and 645:
Nursing Considerations• Use meman
- Page 646 and 647:
Pregnancy category: CIndications an
- Page 648 and 649:
ytoin level and risk of toxicitychl
- Page 650 and 651:
delusions, depression, dizziness, d
- Page 652 and 653:
Children weighing more than 50 kg.
- Page 654 and 655:
• For patients with impaired rena
- Page 656 and 657:
Pregnancy category: CIndications an
- Page 658 and 659:
Adults and adolescents age 18 and o
- Page 660 and 661:
hea related to pseudomembranous col
- Page 662 and 663:
nence and that methadone doesn’t
- Page 664 and 665:
methazolamideMZM, NeptazaneClass an
- Page 666 and 667:
or more. 1 g every 4 to 6 hr (I.M.)
- Page 668 and 669:
methocarbamolCarbacot, Robaxin, Rob
- Page 670 and 671:
MS: Arthralgia, dysarthia, myalgia,
- Page 672 and 673:
methscopolamine bromide; methsuximi
- Page 674 and 675:
Pregnancy category: B (oral form),
- Page 676 and 677:
Make sure to rotate injection sites
- Page 678 and 679:
• Watch closely (especially child
- Page 680 and 681:
increased blood glucose levelisonia
- Page 682 and 683:
tric emptying and peristalsis, thus
- Page 684 and 685:
oral anticoagulants: Decreased anti
- Page 686 and 687:
GI: Constipation, diarrhea, hepatit
- Page 688 and 689:
skin (topical form); erythema, flus
- Page 690 and 691:
changed to q.i.d.DOSAGE ADJUSTMENT
- Page 692 and 693:
methotrexate: Increased risk of met
- Page 694 and 695:
increments, as ordered. Maximum: 5
- Page 696 and 697:
facial flushing, piloerection, rash
- Page 698 and 699:
ENDO: Hot flashes, hyperprolactinem
- Page 700 and 701:
sion, dilute drug with half-normal
- Page 702 and 703:
• Monitor blood, renal, and hepat
- Page 704 and 705:
PATIENT TEACHING• Inform patient
- Page 706 and 707:
with food, with last dose at bedtim
- Page 708 and 709:
• Assess patient for cardiac dysf
- Page 710 and 711:
Nursing Considerations• Modafinil
- Page 712 and 713:
molindone hydrochloride 693Nursing
- Page 714 and 715:
2 hours of taking an antacid. Advis
- Page 716 and 717:
Indications and Dosages To prevent
- Page 718 and 719:
I.V. INJECTIONAdults. 1 to 4 mg by
- Page 720 and 721:
vascular status carefully and frequ
- Page 722 and 723:
to-use flexible bags with 400 mg of
- Page 724 and 725:
ENDO: Cushing’s syndrome, diabete
- Page 726 and 727:
N OnabumetoneRelafenClass and Categ
- Page 728 and 729:
TABLETSAdults. Initial: 40 mg daily
- Page 730 and 731:
cate lack of compliance.• Be awar
- Page 732 and 733:
I.V., I.M., OR SUBCUTANEOUS INJECTI
- Page 734 and 735:
monitor patient’s blood counts an
- Page 736 and 737:
Mechanism of ActionDisplaces opioid
- Page 738 and 739:
musculoskeletal inflammation or pai
- Page 740 and 741:
lets whole and not to break, crush,
- Page 742 and 743:
SKIN: Dermatitis, night sweats, pru
- Page 744 and 745:
Nursing Considerations• Give nate
- Page 746 and 747:
liver injury; use within 14 days of
- Page 748 and 749:
nine levels to assess renal functio
- Page 750 and 751:
cular smooth muscle and endothelial
- Page 752 and 753:
• Monitor blood netilmicin level;
- Page 754 and 755:
was prescribed for hypertension. Su
- Page 756 and 757:
theophylline, tricyclic antidepress
- Page 758 and 759:
enazepril: Possibly increased heart
- Page 760 and 761:
alter amount of grapefruit products
- Page 762 and 763:
• Give drug with food or milk to
- Page 764 and 765:
nitroglycerin 745• When applying
- Page 766 and 767:
over infusion container because dru
- Page 768 and 769:
eta blockers: Decreased cardiac-sti
- Page 770 and 771:
pnea, jaundice, rash, and urticaria
- Page 772 and 773:
Infants. 200,000 units to each side
- Page 774 and 775:
• Don’t give depot injection by
- Page 776 and 777:
severe hepatic disease, including c
- Page 778 and 779:
tablet will disintegrate rapidly in
- Page 780 and 781:
Nursing Considerations• Assess pa
- Page 782 and 783:
lood glucose level—that may contr
- Page 784 and 785:
him to empty package into a small c
- Page 786 and 787:
orphenadrine 767Mechanism of Action
- Page 788 and 789:
oxacillin sodium 769infections (suc
- Page 790 and 791:
or hair, vaginal bleeding, vaginiti
- Page 792 and 793:
worsen anemia.• Assess patient’
- Page 794 and 795:
1,500 mg daily for those weighing 3
- Page 796 and 797:
• If patient complains of GI disc
- Page 798 and 799:
CONTROLLED-RELEASE TABLETS, E.R. TA
- Page 800 and 801:
enlargement, prepubertal closure of
- Page 802 and 803:
dose every 12 hours. For conversion
- Page 804 and 805:
PpaliperidoneInvegaClass and Catego
- Page 806 and 807:
who have or may develop prolonged c
- Page 808 and 809:
SKIN: Rash, urticariaOther: Hyperur
- Page 810 and 811:
Indications and Dosages To treat ga
- Page 812 and 813:
ContraindicationsEvidence of vitami
- Page 814 and 815:
of toxicitydigoxin: Possibly decrea
- Page 816 and 817:
serious reactions (trouble breathin
- Page 818 and 819:
vessels, and inhibit renin release
- Page 820 and 821:
SKIN: Pemphigus, pruritus, rash, ur
- Page 822 and 823:
BICILLIN L-A ONLY)Adults and adoles
- Page 824 and 825:
RESP: Bronchospasm, chest pain or c
- Page 826 and 827:
• Advise patient to report possib
- Page 828 and 829:
improvement and no adverse reaction
- Page 830 and 831:
RESP: CoughSKIN: Canker sores, diap
- Page 832 and 833:
Nursing Considerations• Perphenaz
- Page 834 and 835:
phenelzine sulfate 815Mechanism of
- Page 836 and 837:
Indications and Dosages To treat se
- Page 838 and 839:
PATIENT TEACHING• Instruct patien
- Page 840 and 841:
Mechanism of ActionDirectly stimula
- Page 842 and 843:
Children. 15 to 20 mg/kg at no more
- Page 844 and 845:
• If patient has an NG tube in pl
- Page 846 and 847:
ters, such as catecholamines. Pindo
- Page 848 and 849:
Nursing Considerations• Be aware
- Page 850 and 851:
after piperacillin; use a separate
- Page 852 and 853:
level and toxicitymethotrexate: Dec
- Page 854 and 855:
InteractionsDRUGScyclosporine, eryt
- Page 856 and 857:
els, especially in patients with a
- Page 858 and 859:
K-10 (CAN), K 10, Kalium Durules(CA
- Page 860 and 861:
insulin, laxatives, sodium bicarbon
- Page 862 and 863:
potassium andsodium phosphatesK-Pho
- Page 864 and 865:
given concurrently with atropine 2
- Page 866 and 867:
• Instruct patient to notify pres
- Page 868 and 869:
ed, or known pregnancy because drug
- Page 870 and 871:
Nursing Considerations• Use prava
- Page 872 and 873:
(PREDNISOLONE SODIUM PHOSPHATE); OR
- Page 874 and 875:
prednisone 855injury for up to 12 m
- Page 876 and 877:
notify prescriber immediately about
- Page 878 and 879:
Mechanism of ActionPrevents seizure
- Page 880 and 881:
effects of these drugs, possibly ex
- Page 882 and 883:
after last I.V. dose.PATIENT TEACHI
- Page 884 and 885:
(except for phenmetrazine)astemizol
- Page 886 and 887:
To treat secondary amenorrheaTABLET
- Page 888 and 889:
occur when patient sits on injectio
- Page 890 and 891:
when used as an antihistamine; pylo
- Page 892 and 893:
Nursing Considerations• Assess pa
- Page 894 and 895:
e added to propofol solution in qua
- Page 896 and 897:
propranolol hydrochloride 877XL TAB
- Page 898 and 899:
• Because drug’s negative inotr
- Page 900 and 901:
Adverse ReactionsCNS: WeaknessCV: B
- Page 902 and 903:
with other antitubercular drugsTABL
- Page 904 and 905:
Q R SquazepamDoralClass, Category,
- Page 906 and 907:
increased to 400 mg b.i.d. on day 6
- Page 908 and 909:
FOODSlow-salt milk, salt substitute
- Page 910 and 911:
Nursing Considerations• Give I.M.
- Page 912 and 913:
cillin 1000 mg b.i.d for 7 days and
- Page 914 and 915:
infectionOther: Anaphylaxis, angioe
- Page 916 and 917:
CAPSULES, EFFERVESCENT GRANULES,EFF
- Page 918 and 919:
E.R. TABLETSAdults. Initial: 500 mg
- Page 920 and 921:
I.V. infusion, as prescribed, to re
- Page 922 and 923:
epaglinide 903Mechanism of ActionRe
- Page 924 and 925:
eserpine 905• Advise patient to w
- Page 926 and 927:
dipyridamole), strontium-89 chlorid
- Page 928 and 929:
synthesis by binding to DNA-depende
- Page 930 and 931:
zole to be discontinued immediately
- Page 932 and 933:
50 mg every 2 wk.DOSAGE ADJUSTMENT
- Page 934 and 935:
6 mg daily, use 4.6 mg/24 hr, with
- Page 936 and 937:
peripheral vascular disease because
- Page 938 and 939:
type 2 (D 2 ) receptors within the
- Page 940 and 941:
osuvastatin calcium 921patients wit
- Page 942 and 943:
proate, initial dosage reduced to l
- Page 944 and 945:
onds, and exhale slowly.• Advise
- Page 946 and 947:
• Dissolve tablets in 4 to 8 ounc
- Page 948 and 949:
ContraindicationsAngle-closure glau
- Page 950 and 951:
ate toxicitymexiletine: Decreased b
- Page 952 and 953:
such conditions as dementia, severe
- Page 954 and 955:
appropriate, in patients with hepat
- Page 956 and 957:
Mechanism of ActionInhibits central
- Page 958 and 959:
EENT: Blurred vision; change in col
- Page 960 and 961:
This action reduces the formation o
- Page 962 and 963:
immediately. Then rinse glass with
- Page 964 and 965:
ORAL POWDERAdults and adolescents.
- Page 966 and 967:
RESP: Cough, dyspnea, upper respira
- Page 968 and 969:
several hours, be aware that it’s
- Page 970 and 971:
nacin or its components, uncontroll
- Page 972 and 973:
esponse of corticosteroids or corti
- Page 974 and 975:
effect and, possibly, other beta-bl
- Page 976 and 977:
Children weighing less than 45 kg (
- Page 978 and 979:
• Stop drug for several days, as
- Page 980 and 981:
eta-lactam antibiotics: Inactivatio
- Page 982 and 983:
hydantoins, oral anticoagulants, or
- Page 984 and 985:
sulfamethoxazoleApo-Sulfamethoxazol
- Page 986 and 987:
decreased blood level of digoxinfol
- Page 988 and 989:
aspirin or acetaminophen.• Advise
- Page 990 and 991:
an enzyme needed to synthesizeprost
- Page 992 and 993:
sumatriptansuccinateImitrexClass an
- Page 994 and 995:
tacrine hydrochloride 975tacrinehyd
- Page 996 and 997:
CAPSULESAdults having kidney transp
- Page 998 and 999:
tadalafil 979• Monitor patient’
- Page 1000 and 1001:
tamoxifen citrateApo-Tamox (CAN), G
- Page 1002 and 1003:
RESP: Respiratory impairmentSKIN: P
- Page 1004 and 1005:
IncompatibilitiesDon’t mix telava
- Page 1006 and 1007:
• Before administering the first
- Page 1008 and 1009:
alcohol use: Increased CNS depressi
- Page 1010 and 1011:
(such as abdominal pain or swelling
- Page 1012 and 1013:
pruritus, rash, urticariaOther: Ang
- Page 1014 and 1015:
teriparatide 995Mechanism of Action
- Page 1016 and 1017:
Possibly reduced contraceptive reli
- Page 1018 and 1019:
dence of a venous thromboembolic ev
- Page 1020 and 1021:
vidualized in mg/kg daily as prescr
- Page 1022 and 1023:
tramadol: Additive CNS effects, inc
- Page 1024 and 1025:
• To prepare 0.4% solution, dilut
- Page 1026 and 1027:
thioridazine 1007• Frequently mon
- Page 1028 and 1029:
peripheral edema, tachycardiaEENT:
- Page 1030 and 1031:
WARNING Be aware that thyroid hormo
- Page 1032 and 1033:
ness, EEG abnormalities, hostility,
- Page 1034 and 1035:
ticlopidine hydrochloride 1015Mecha
- Page 1036 and 1037:
Adverse ReactionsCNS: Asthenia, chi
- Page 1038 and 1039:
timolol maleateApo-Timol (CAN), Blo
- Page 1040 and 1041:
ContraindicationsBreast-feeding, hy
- Page 1042 and 1043:
when a spinal puncture is performed
- Page 1044 and 1045:
eyes because it may irritate them o
- Page 1046 and 1047:
Nursing Considerations• Be aware
- Page 1048 and 1049:
nebulizer parts (except tubing) for
- Page 1050 and 1051:
Nursing Considerations• Tocilizum
- Page 1052 and 1053:
to detect.• Assess patient with t
- Page 1054 and 1055:
• Anticipate that drug may precip
- Page 1056 and 1057:
increase the risk of serious advers
- Page 1058 and 1059:
the risk of overly-rapid correct of
- Page 1060 and 1061:
torsemideDemadexClass and CategoryC
- Page 1062 and 1063:
igors, seizures, serotonin syndrome
- Page 1064 and 1065:
• Explain that drug may cause diz
- Page 1066 and 1067:
hypertensive crisis, seizures, or d
- Page 1068 and 1069:
GU: Anorgasmia, ejaculation disorde
- Page 1070 and 1071:
it shouldn’t be used after 72 hou
- Page 1072 and 1073:
To treat chronic idiopathic thrombo
- Page 1074 and 1075:
voluted tubules and cortical collec
- Page 1076 and 1077:
eathing, throat tightness, nausea,
- Page 1078 and 1079:
full glass of milk or water to mini
- Page 1080 and 1081:
thermoregulation. Encourage her to
- Page 1082 and 1083:
species, Escherichia coli, Klebsiel
- Page 1084 and 1085:
Nursing Considerations• Watch pat
- Page 1086 and 1087:
tubocurarine chloride 1067empty sto
- Page 1088 and 1089:
U V Wurea(carbamide)UreaphilClass a
- Page 1090 and 1091:
Nursing Considerations• To preven
- Page 1092 and 1093:
can’t be confirmed or if patient
- Page 1094 and 1095:
SKIN: Alopecia, diaphoresis, erythe
- Page 1096 and 1097:
caused by Clostridium difficile and
- Page 1098 and 1099:
pus cavernosum, producing an erecti
- Page 1100 and 1101:
vasopressin 1081adverse reactions t
- Page 1102 and 1103:
cimetidine: Decreased clearance and
- Page 1104 and 1105:
• slows AV conduction time and pr
- Page 1106 and 1107:
InteractionsDRUGSphenytoin: Decreas
- Page 1108 and 1109:
tive effect of benzodiazepinescalci
- Page 1110 and 1111:
feres with the clotting cascade. By
- Page 1112 and 1113:
X Y ZzafirlukastAccolateClass and C
- Page 1114 and 1115:
plon therapy because it increases r
- Page 1116 and 1117:
altered mental status, nausea, vomi
- Page 1118 and 1119:
patients previously treated for Wil
- Page 1120 and 1121:
like symptoms, injection site pain,
- Page 1122 and 1123:
disorders must be treated before zo
- Page 1124 and 1125:
Indications and Dosages To provide
- Page 1126:
zonisamide 1107• Monitor patient
- Page 1130 and 1131:
Insulin Preparations 1111Insulin Pr
- Page 1132 and 1133:
Insulin Preparations (continued)CAT
- Page 1134 and 1135:
Selected Ophthalmic Drugs 1115Selec
- Page 1136 and 1137:
Selected Ophthalmic Drugs 1117Selec
- Page 1138 and 1139:
Selected Ophthalmic Drugs 1119Selec
- Page 1140 and 1141:
Selected Ophthalmic Drugs 1121Selec
- Page 1142 and 1143:
Selected Ophthalmic Drugs 1123Selec
- Page 1144 and 1145:
Antihistamines 1125Antihistamines (
- Page 1146 and 1147:
Selected Topical Drugs 1127Selected
- Page 1148 and 1149:
Selected Topical Drugs 1129Selected
- Page 1150 and 1151:
Selected Topical Drugs (continued)S
- Page 1152 and 1153:
Selected Topical Drugs 1133Selected
- Page 1154 and 1155:
Selected Topical Drugs 1135Selected
- Page 1156 and 1157:
Selected Topical Drugs 1137Selected
- Page 1158 and 1159:
Selected Topical Drugs 1139Selected
- Page 1160 and 1161:
Selected Topical Drugs 1141Selected
- Page 1162 and 1163:
Selected Antivirals 1143Selected An
- Page 1164 and 1165:
Selected Antivirals 1145Selected An
- Page 1166 and 1167:
Selected Antivirals 1147Selected An
- Page 1168 and 1169:
Selected Antineoplastic Drugs 1149S
- Page 1170 and 1171:
Selected Antineoplastic Drugs (cont
- Page 1172 and 1173:
Selected Antineoplastic Drugs (cont
- Page 1174 and 1175:
Selected Antineoplastic Drugs (cont
- Page 1176 and 1177:
Selected Antineoplastic Drugs (cont
- Page 1178 and 1179:
Selected Antineoplastic Drugs (cont
- Page 1180 and 1181:
Selected Antineoplastic Drugs (cont
- Page 1182 and 1183:
Selected Antineoplastic Drugs (cont
- Page 1184 and 1185:
Selected Antineoplastic Drugs (cont
- Page 1186 and 1187:
Selected Antihypertensive Combinati
- Page 1188 and 1189:
Selected Antihypertensive Combinati
- Page 1190 and 1191:
Selected Antihypertensive Combinati
- Page 1192 and 1193:
Selected Antihypertensive Combinati
- Page 1194 and 1195:
Vitamins 1175op. Water-soluble vita
- Page 1196 and 1197:
Vitamins 1177OTHER INDICATIONS AND
- Page 1198 and 1199:
Vitamins 1179OTHER INDICATIONS AND
- Page 1200 and 1201:
Vitamins 1181OTHER INDICATIONS AND
- Page 1202 and 1203:
Vitamins 1183OTHER INDICATIONS AND
- Page 1204 and 1205:
Vitamins 1185OTHER INDICATIONS AND
- Page 1206 and 1207:
Interferons 1187stance believed to
- Page 1208 and 1209:
Interferons 1189ADVERSEREACTIONSNUR
- Page 1210 and 1211:
Interferons 1191ADVERSEREACTIONSNUR
- Page 1212 and 1213:
Compatible Drugs in a Syringe 1193h
- Page 1214 and 1215:
Drug Formulas and Calculations 1195
- Page 1216 and 1217:
Drug Formulas and Calculations 1197
- Page 1218 and 1219:
Weights and Equivalents 1199Weights
- Page 1220 and 1221:
Equianalgesic Doses for Opioid Agon
- Page 1222:
Abbreviations 1203Abbreviations (co
- Page 1226 and 1227:
Index 1207• Generic and alternate
- Page 1228 and 1229:
Anaflex 750, 925Anafranil, 253anagr
- Page 1230 and 1231:
Azilect, 899azithromycin, 118-120Az
- Page 1232 and 1233:
Cardura-4, 345carisoprodol, 177-178
- Page 1234 and 1235:
Cutivate, 1134tcyanocobalamin,1178-
- Page 1236 and 1237:
disulfiram, 333-335Ditropan, 777Dit
- Page 1238 and 1239:
ethambutol hydrochloride,410ethchlo
- Page 1240 and 1241:
Genprin, 104Gen-Ranitidine, 896Gen-
- Page 1242 and 1243:
interferon alfa-2a,recombinant, 115
- Page 1244 and 1245:
Liquiprin Elixir, 23Liquiprin Infan
- Page 1246 and 1247:
Mezlin, 672mezlocillin sodium, 672-
- Page 1248 and 1249:
Nitrogard, 743nitrogen mustard, 115
- Page 1250 and 1251:
oxybutynin chloride,777-778oxycodon
- Page 1252 and 1253:
prednisolone, 852-855prednisolone a
- Page 1254 and 1255:
Rivotril, 254rizatriptan benzoate,9
- Page 1256 and 1257:
Taclonex, 1138tTaclonex Scalp, 1138
- Page 1258 and 1259:
trifluoperazine hydrochloride,1057-
- Page 1260 and 1261:
Index 1241Zantac EFFERdose Tablets,
- Page 1262 and 1263:
WEIGHT (POUNDS)177 181 186 191 196
- Page 1264 and 1265:
Mechanism of Action Illustrations (